Su rol en la génesis de la enfermedad cardiovascular | 25 ENE 16

Hiperinsulinemia (y resistencia a la insulina)

Las causas físicas, biológicas y epidemiológicas que vinculan la hiperinsulinemia con la enfermedad metabólica y vascular. Fisiopatología y diagnóstico de la hiperinsulinemia.
INDICE:  1. Página 1 | 2. Página 1
Página 1

1. Harris S. Hyperinsulinism and dysinsulinism. Journal of the American Medical Association. 1924;83(10):729-33. 
2. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004 May 1, 2004;24(5):816-23. 
3. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(suppl 3):S16-S21. 
4. Zavaroni I, Bonini L, Gasparini P, Barilli A, Zuccarelli A, Dall'Aglio E, et al. Hyperinsulinemia in a normal population as a predictor of non—insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism. 1999;48(8):989-94. 
5. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-28. 
6. Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal state hyperinsulinemia in healthy normoglycemic adults heralds dysglycemia after more than two decades of follow up. Diabetes Metab Res Rev. 2012;28(7):618-24. 
7. Kraft JR. Diabetes epidemic and you. 2nd ed. Victoria, BC: Trafford; 2011. 
8. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Investig. 1960;39(7). 
9. Labtests. Reference Intervals 2012 [cited 2013 January 29]. Available from: 
10. Kraft JR. Detection of diabetes mellitus in situ (occult diabetes). Laboratory Medicine. 1975;6(2):10-22. 
11. Waikato District Health Board. Laboratory test reference guide Hamilton2015 [cited 2015 September 16]. Available from: 
12. Lan-Pidhainy X, Wolever T. Are the glycemic and insulinemic index values of carbohydrate foods similar in healthy control, hyperinsulinemic and type 2 diabetic patients? Eur J Clin Nutr. 2011;65(6):727-34. 
13. Nilsson P, Nilsson JÅ, Hedblad B, Eriksson KF, Berglund G. Hyperinsulinaemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: The Malmö Preventive Project. J Intern Med. 2003;253(2):136-45. 
14. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959-65. 
15. McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001 March 1, 2001;24(3):460-4. 
16. Iwase H, Kobayashi M, Nakajima M, Takatori T. The ratio of insulin to C-peptide can be used to make a forensic diagnosis of exogenous insulin overdosage. Forensic Sci Int. 2001;115(1–2):123-7. 
17. Wilcox G. Insulin and insulin resistance. Clinical Biochemist Reviews. 2005;26(2):19-39. 
18. Grunberger G, Taylor SI, Dons RF, Gorden P. Insulin receptors in normal and disease states. Clin Endocrinol Metab. 1983 Mar;12(1):191-219. 
19. Schnurr TM, Reynolds AJ, Komac AM, Duffy LK, Dunlap KL. The effect of acute exercise on GLUT4 levels in peripheral blood mononuclear cells of sled dogs. Biochemistry and Biophysics Reports. 2015 7;2:45-9. 
20. Farooqui AA, Farooqui T, Panza F, Frisardi V. Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci. 2012 Mar;69(5):741-62. 
21. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, et al. Hypothesis: Could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30(1):96-116. 
22. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes. 1992 May 1, 1992;41(5):571-80. 
23. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 December 1, 2000;49(12):2063-9. 
24. Björntorp PE, Rosmond R. Hypothalamic origin of the metabolic syndrome x. Ann N Y Acad Sci. 1999;892(1):297-307. 
25. Porte D, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002;60:S20-S9. 
26. Lustig RH, Sen S, Soberman JE, Velasquez-Mieyer PA. Obesity, leptin resistance, and the effects of insulin reduction. International Journal of Obesity & Related Metabolic Disorders. 2004;28(10):1344-8. 
27. Taylor D, Paton C, Kerwin R, editors. The Maudsley prescribing guidelines. 9th ed: Informa Healthcare; 2007. 
28. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990 June 1, 1990;13(6):631-54. 
29. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: A consensus report. CA Cancer J Clin. 2010;60(4):207-21. 
30. Feng L, Chong MS, Lim WS, Lee TS, Collinson SL, Yap P, et al. Metabolic syndrome and amnestic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 findings. J Alzheimer's Dis. 2013;34(3):649-57. 
31. Yan W, Li X. Impact of diabetes and its treatments on skeletal diseases. Front Med. 2013 Mar;7(1):81-90. 
32. Mehran Arya E, Templeman Nicole M, Brigidi GS, Lim Gareth E, Chu K-Y, Hu X, et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 2012 12/5/;16(6):723-37. 
33. Monzo HJ, Park TI, Dieriks VB, Jansson D, Faull RL, Dragunow M, et al. Insulin and IGF1 modulate turnover of polysialylated neuronal cell adhesion molecule (PSA-NCAM) in a process involving specific extracellular matrix components. J Neurochem. 2013. 
34. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res. 2011;69:26R-33R. 
35. Kraft JR. Hyperinsulinemia: A merging history with idiopathic tinnitus, vertigo, and hearing loss. International Tinnitus Journal. 1998;4(2):127-30. 
36. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol. 2002;29(7):1350-5. 
37. Bayir H. Reactive oxygen species. Crit Care Med. 2005;33(12):S498-S501. 
38. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J. 1996;313:17-29. 
39. Eto K, Asada T, Arima K, Makifuchi T, Kimura H. Brain hydrogen sulfide is severely decreased in Alzheimer's disease. Biochem Biophys Res Commun. 2002 5/24/;293(5):1485-8. 
40. Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Insulin and atherosclerosis: How are they related? Diabetes Metab. 2013 (0). 
41. Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A “glycoxidation-centric” point of view. Nutr Metab Cardiovasc Dis. 2013 (0). 
42. Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006;55(6):1807-12. 
43. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. The American journal of medicine. 1974;57(4):551-60. 
44. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320-30. 
45. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes. 2004 May 1, 2004;53(5):1253-60. 
46. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005 Nov;42(5):987-1000. 
47. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20(6):935-42. 
48. Matafome P, Santos-Silva D, Sena CM, Seiça R. Common mechanisms of dysfunctional adipose tissue and obesity- related cancer. Diabetes Metab Res Rev. 2013. 
49. Martin SS, Qasim A, Reilly MP. Leptin resistance: A possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52(15):1201-10. 
50. Henderson JR. Serum-insulin or plasma-insulin ? The Lancet. 1970;296(7672):545-7. 
51. Feldman JM, Chapman BA. Radioimmunoassay of insulin in serum and plasma. Clin Chem. 1973;19(11):1250-4. 
52. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-95. 
53. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability characteristics of simple indices of insulin resistance: Implications for research applications. The Journal of Clinical Endocrinology & Metabolism. 2001;86(11):5457-64. 
54. Samaras K, McElduff A, Twigg SM, Proietto J, Prins JB, Welborn TA, et al. Insulin levels in insulin resistance: Phantom of the metabolic opera? Med J Aust. 2006;185(3):159. 
55. Samaras K, McElduff A, Twigg SM, Proietto J, Prins JB, Welborn TA, et al. Insulin levels in insulin resistance: Phantom of the metabolic opera? Med J Aust. 2006;185(3):159. 
56. Mari A, Pacini G, Murphy E, Ludvik B, Nolan J. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24(3):539-48. 
57. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps Diabetes Care. 2012 July 1, 2012;35(7):1605-10. 
58. Diamond MP, Thornton K, Connolly-Diamond M, Sherwin RS, DeFronzo RA. Reciprocal variations in insulin-stimulated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J Soc Gynecol Investig. 1995;2(5):708-15. 
59. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. Journal of Clinical Endocrinology & Metabolism. 2000 July 1, 2000;85(7):2402-10. 
60. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization, 1999. 
61. Schmiegelow MD, Hedlin H, Stefanick ML, Mackey RH, Allison M, Martin LW, et al. Insulin resistance and risk of cardiovascular disease in postmenopausal women: A cohort study from the Women’s Health Initiative. Circulation: Cardiovascular Quality and Outcomes. 2015 May 1, 2015;8(3):309-16. 
62. Hayashi T, Boyko EJ, Sato KK, McNeely MJ, Leonetti DL, Kahn SE, et al. Patterns of insulin concentration during the OGTT predict the risk of type 2 diabetes in Japanese Americans. Diabetes Care. 2013 May 1, 2013;36(5):1229-35. 
63. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73-8. 
64. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease: Vascular complications of diabetes. BMJ. 2000;320(7241):1062. 
65. Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy--fact or fiction? Herz. 2011;36(2):102-15. 
66. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol. 2011;48(3):173-81. 
67. Rask-Madsen C, King GL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nature Clinical Practice Endocrinology & Metabolism. 2007;3(1):46-56. 
68. Kaaja R, Rönnemaa T. Gestational diabetes: Pathogenesis and consequences to mother and offspring. The review of diabetic studies: RDS. 2008;5(4):194. 
69. Flores-Riveros JR, McLenithan JC, Ezaki O, Lane MD. Insulin down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover. Proceedings of the National Academy of Sciences. 1993;90(2):512-6. 
70. Scheepers A, Joost H, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. J Parenter Enteral Nutr. 2004 September 1, 2004;28(5):364-71. 
71. Medina-Santillán R, López-Velázquez JA, Chávez-Tapia N, Torres-Villalobos G, Uribe M, Méndez-Sánchez N. Hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev. 2013. 
72. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. The American journal of medicine. 1999;107(5):450-5. 
73. Marques-Vidal P, Bastardot F, Känel R, Paccaud F, Preisig M, Waeber G, et al. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol (Oxf). 2013;78(2):232-41. 
74. Choi SM, Tucker DF, Gross DN, Easton RM, DiPilato LM, Dean AS, et al. Insulin regulates adipocyte lipolysis via an Akt-independent signaling pathway. Mol Cell Biol. 2010 November 1, 2010;30(21):5009-20. 
75. Swinburn BA, Sacks G, Lo SK, Westerterp KR, Rush EC, Rosenbaum M, et al. Estimating the changes in energy flux that characterize the rise in obesity prevalence. Am J Clin Nutr. 2009 June 1, 2009;89(6):1723-8. 
76. Yu JH, Shin MS, Kim DJ, Lee JR, Yoon SY, Kim SG, et al. Enhanced carbohydrate craving in patients with poorly controlled Type 2 diabetes mellitus. Diabetic Medicine. 2013. 
77. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? Exp Gerontol. 2011;46(4):225-32. 
78. Razay G, Wilcock G. Hyperinsulinaemia and Alzheimer's disease. Age Ageing. 1994;23:396-9. 
79. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer’s. Journal of Alzheimer’s Disease. 2008;13:241-53. 
80. Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens P. Vascular dementia. Neuroimaging in Dementia. Berlin: Springer; 2011. p. 137-76. 
81. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid- beta peptide in Alzheimer's disease: Review and hypothesis. Neurobiology of Aging. 2006;27(2):190-8. 
82. Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes, metabolic syndrome and obesity: targets and therapy. 2013;6:79. 
83. Kim B, McLean LL, Philip SS, Feldman EL. Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology. 2011;152(10):3638-47. 
84. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 betaand VEGF. J Clin Investig. 2002;109(6):805-15. 
85. Kang D-H, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002 March 1, 2002;13(3):806-16. 
86. Hamer RA, El Nahas AM. The burden of chronic kidney disease: Is rising rapidly worldwide. BMJ. 2006;332(7541):563. 
87. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008 June 1, 2008;57(6):1446-54. 



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024